autoimmune diseases

News

Novartis abandons Fabhalta trial in lupus nephritis

A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for Fabhalta to include lupus nephritis.

News

Woman and man back to back, B&W photograph

Females with autoimmune disease 'less likely to be believed'

Women and girls with autoimmune diseases are more likely to have their condition misdiagnosed as psychiatric or psychosomatic than males, study finds.

News

Novartis taps China's Abogen for autoimmunity TCE

Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.

News

A young woman covers her face with her hands

Amgen's Horizon buyout delivers Sjögren's disease win

Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.

News

Novartis halts CAR-T trials after patient deaths

Novartis stops eight trials of CAR-T rap-cel in autoimmune diseases after three deaths, with BMS also halting studies of zola-cel as a precaution.

News

Acquisitive Lilly offers $2.88bn for Merida Bio

Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.

Novartis abandons Fabhalta trial in lupus nephritis

Females with autoimmune disease 'less likely to be believed'

Novartis taps China's Abogen for autoimmunity TCE

Amgen's Horizon buyout delivers Sjögren's disease win

Novartis halts CAR-T trials after patient deaths

Acquisitive Lilly offers $2.88bn for Merida Bio

Astellas pays $285m for Audax cancer drug, and other deals

Discover a new era of healthcare panel engagement: Grounded ...

autoimmune diseases

Editor's Picks